Clinical Utility of PET-FDG Imaging in Differentiation of Benign from Malignant Adrenal Masses in Lung Cancer

Utilisation of combined18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement

“…Several reports have documented the effectiveness of standalone fluorine-18 fludeoxyglucose ( 18 F-FDG) positron emission tomography (PET) to differentiate benign from malignant adrenal lesions [8][9][10]. Interest has focused on the ability of integrated in-line PET/CT to definitively characterise these lesions given that this technique combines the anatomical and densitometrical applications of CT and the functional and metabolic advantages of PET.…”

“…Interest has focused on the ability of integrated in-line PET/CT to definitively characterise these lesions given that this technique combines the anatomical and densitometrical applications of CT and the functional and metabolic advantages of PET. Several studies have reported PET/CT's high sensitivity, specificity and accuracy for detecting adrenal metastatic lesions [7][8][9][10].PET/CT can also be used as a non-invasive method to help assess the lesion, facilitating diagnosis and treatment decisions. The purpose of our study was to investigate whether PET/CT can reliably detect differences between malignant and benign lesions, tumour characteristics associated with the location of the primary cancer and predictors for adrenal metastasis.…”

“…Characterisation of these adrenal lesions is therefore critical to stage the primary disease, direct therapy and predict prognosis. Although CT and MRI are typically used to characterise a lesion, a small but important number of adrenal lesions are found to be indeterminate on crosssectional images [7][8][9].…”

“…Characterisation of these adrenal lesions is therefore critical to stage the primary disease, direct therapy and predict prognosis. Although CT and MRI are typically used to characterise a lesion, a small but important number of adrenal lesions are found to be indeterminate on crosssectional images [7][8][9].Several reports have documented the effectiveness of standalone fluorine-18 fludeoxyglucose ( 18 F-FDG) positron emission tomography (PET) to differentiate benign from malignant adrenal lesions [8][9][10]. Interest has focused on the ability of integrated in-line PET/CT to definitively characterise these lesions given that this technique combines the anatomical and densitometrical applications of CT and the functional and metabolic advantages of PET.…”

Fluorodeoxyglucose-Positron-Emission Tomography/Computed Tomography Imaging for Adrenal Masses in Patients with Lung Cancer: Review and Diagnostic Algorithm

“…Of the 104 articles identified, 24 contained clinical information dealing with metastasis to the adrenal gland while 80 used PET nonspecifically or specifically to other organs (thorax, mediastinum, brain, liver, etc). Of these 24 studies, 8 were identified to contain reportable pertinent oncologic information, including at least 50% of the study population with NSCLC and concomitant adrenal lesions evaluated by FDG-PET/CT [6][7][8][9][10][11][12] or FDG-PET. 13 The FDG-PET only study was excluded because PET-only literature is considered obsolete compared with PET/CT.…”